Runatek Announces the Sotiras, a Device that Could Prevent Opioid Addiction
For Immediate Release: 03/16/2021
Media Relations The Runatek Corporation Info@Runatek.Com
Runatek Announces the Sotiras, a Device that Could Prevent Opioid Addiction Medical Technology Startup Unveils Device with the Goal of Ending the Opioid Crisis
DALLAS, TX. – Runatek, a medical technology startup, unveiled plans today for a medical device that could prevent opioid addiction. The device, which has been dubbed the “Sotiras” (Greek for “savior”), will help patients maintain set concentrations of prescription pain medication in their bloodstream while managing chronic pain. The Sotiras announcement comes after months of research and development, and one week ahead of an Indiegogo crowdfunding campaign to develop advanced prototypes.
Of the potential for the device, Runatek CEO Matthew Lucci said, “By utilizing the Sotiras, patients would be able to manage their chronic pain without developing a dependency or addiction to prescription opioids. This will revolutionize the way that we approach pain management, and ultimately, would end the opioid crisis in America.”
Runatek will be launching a crowdfunding campaign on Indiegogo on March 23, 2021 to raise funds for advanced prototypes ahead of the FDA approvals process. With opioid overdose deaths soaring during the covid-19 pandemic, this technology has never been needed more than it is today. Meeting the crowdfunding goal of $12,500 will be the next tangible step toward ending the opioid crisis by focusing on addiction prevention.
About Runatek: The Runatek Corporation is a medical technology startup based in Dallas, TX. Founded in 2020, Runatek is working to end the opioid crisis with innovative technology. The company posts regular updates on all major social media platforms @Runatek.